Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

A-431 ¼¼Æ÷ÁÖÀÇ ¹æ»ç¼± ¹× Ç×¾ÏÁ¦ÀÇ °¨¼ö¼º¿¡ °üÇÑ ½ÇÇèÀû ¿¬±¸

Experimental Study on the Radiosensitivity and Chemosensitivity of A-431 Cell Line

Ä¡°ú¹æ»ç¼± 1999³â 29±Ç 1È£ p.327 ~ 339
È«¼º¿ì, ÃÖÀº¼÷, °í±¤ÁØ,
¼Ò¼Ó »ó¼¼Á¤º¸
È«¼º¿ì (  ) - ÀüºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¹æ»ç¼±Çб³½Ç
ÃÖÀº¼÷ (  ) - ÀüºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¹æ»ç¼±Çб³½Ç
°í±¤ÁØ (  ) - ÀüºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­¾Ç¾È¸é¹æ»ç¼±Çб³½Ç

Abstract

¹æ»ç¼± ¹× Ç×¾ÏÁ¦ÀÇ ¼¼Æ÷µ¶¼ºÀ» ¾Ë¾Æº¸±â À§ÇÏ¿©, ½ÇÇè½Ç¿¡¼­ ¹è¾çµÈ human epidermoid
carcinoma A-431 ¼¼Æ÷ÁÖ¸¦ ´ë»óÀ¸·Î ¹æ»ç¼± ´Üµ¶Á¶»ç±ºÀº 2, 4, 6, 8, 10Gy¿Í ¹æ»ç¼±À» ´Ü
ȸ Á¶»çÇÏ¿´À¸¸ç, Ç×¾ÏÁ¦ ´Üµ¶Åõ¿©±ºÀº 2¥ìg/§¢ ³óµµÀÇ bloomycin ¶Ç´Â cisplatinÀ» ´Üµ¶Åõ
¿©ÇÏ¿´´Ù. ¶ÇÇÑ ¹æ»ç¼±Á¶»ç¿Í Ç×¾ÏÁ¦¸¦ º´¿ëÇÑ °æ¿ì¿¡´Â 2, 4, 6, 8, 10GyÀÇ ¹æ»ç¼±À» ´ÜȸÁ¶
»çÇÑ Á÷ÈÄ 2¥ìg/§¢ ³óµµÀÇ bleorrlycin ¶Ç´Â cisplactinÀ» Åõ¿©ÇÏ¿´´Ù. °¢°¢ÀÇ ½ÇÇè¹æ¹ý¿¡ µû
¸¥ ¼¼Æ÷»ýÁ¸À²À» ±¸ÇÏ°í ¼¼Æ÷»ýÁ¸°î¼±À» ÀÛ¼ºÇÑ ÈÄ ¼¼Æ÷µ¶¼ºÀ» Æò°¡ÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú
¸¦ ¾ò¾ú´Ù.
1. A-431 ¼¼Æ÷ÁÖ¿¡ 2GyÀÇ ¹æ»ç¼±À» ´Üµ¶Á¶»çÇÑ °æ¿ì ¼¼Æ÷»ýÁ¸À²Àº 0.99À̾úÀ¸¸ç, ´ëÁ¶±º
°ú À¯ÀÇÇÑ ¼¼Æ÷»ýÁ¸À²ÀÇ Â÷ÀÌ´Â ¾ø¾ú´Ù(P>0.05). ±×·¯³ª 4, 6, 8, 10GyÀÇ ¹æ»ç¼±·®¿¡¼­´Â ´ë
Á¶±º°ú À¯ÀÇÇÑ ¼¼Æ÷»ýÁ¸À²ÀÇ Â÷ÀÌ°¡ ÀÖ¾ú´Ù(P<0.05).
2. A-431 ¼¼Æ÷ÁÖ¿¡ bleomycin ¶Ç´Â cisplatinÀ» ´Üµ¶Åõ¿©ÇÑ °æ¿ì ´ëÁ¶±º°ú À¯ÀÇÇÑ ¼¼Æ÷»ý
Á¸À²ÀÇ Â÷ÀÌ°¡ ÀÖ¾ú°í, cisplatinÀÌ bleomycinº¸´Ù ¼¼Æ÷µ¶¼ºÀÌ ´õ ÄÇ´Ù(P<0.05).
3. A-431¼¼Æ÷ÁÖ¿¡ ¹æ»ç¼±Á¶»ç¿Í bleomycin ¶Ç´Â cisplatinÀ» º´¿ëÇÑ °æ¿ì ¹æ»ç¼±À» ´Üµ¶Á¶
»çÇÑ °æ¿ì¿¡ ºñÇÏ¿© 2, 4, 6, 8, 10GyÀÇ ¸ðµç ¹æ»ç¼±·®¿¡¼­ À¯ÀÇÇÑ ¼¼Æ÷»ýÁ¸À²ÀÇ Â÷ÀÌ°¡ ÀÖ
¾ú´Ù(P<0.05).
4. A-431 ¼¼Æ÷ÁÖ¿¡ ¹æ»ç¼±Á¶»ç¿Í bleomycin ¶Ç´Â cisplatinÀ» º´¿ëÇÑ °æ¿ì 2, 4GyÀÇ ¹æ»ç
¼±·®¿¡¼­´Â µÎ ±º»çÀÌÀÇ ¼¼Æ÷»ýÁ¸À²ÀÇ Â÷ÀÌ°¡ ÀÖ¾úÀ¸³ª(P<0.05), 6, 8, 10GyÀÇ ¹æ»ç¼±·®¿¡¼­
´Â µÎ ±º»çÀÌÀÇ ¼¼Æ÷»ýÁ¸À²ÀÇ Â÷ÀÌ´Â ¾ø¾ú´Ù(P>0.05).
#ÃÊ·Ï#
Objectives : The purpose of this study was to aid in the prediction of tumor cell
tolerance to radiotherapy and/or chemotherapy.
Material and Methods : Human epidermoid carcinoma A-431 cell lines were irradiated
by 2, 4, 6, 8, 10Gy at a dose rate of 210cGy/min using 60Co Irradiator
ALDORADO 8 and then were exposed to bleomycin or cisplatin at concentration of 21¥ì
g/§¢ for 1 hour. The viable cells were determined for each radiation dose and/or each
drug at the 4th day and cell surviving curves were obtained using semiautomated MTT
assay.
Results : The surviving fraction after irradiation of 2Gy was 0.99. and there was not
significant difference of surviving fraction in comparison with the control group on
A-431 cell line(P>0.05). But there were significant differences of surviving fractions at
doses of 4, 6, 8, 10Gy in comparison with the control group(P<0.05). The cytotoxicity of
bleomycin or cisplatin was significantly different in comparison with the control group
on A-431 cell line (P<0.05) And the cytotoxicity of cisplatin was greater than that of
bleomycin on A-431 cell line (P<0.05). There were significant differences of surviving
fractions after irradiation of 2, 4, 6, 8, 10Gy with bleomycin or cisplatin in comparison
with each group of irradiation only on A-431 cell line(P<0.05). There were significant
differences of surviving fractions between the groups o# irradiation with bleomycin and
cisplatin at doses of 2, 4Gy(P<0.05), but there were not significant differences of
surviving fractions at doses of 6, 8, 10Gy on A-431 cell line (P>0.05).

Å°¿öµå

radiosensitivity; chemosensitivity; A-431 cell line;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸